122 related articles for article (PubMed ID: 28099196)
1. Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
Kim S; Sohn HJ; Lee HJ; Sohn DH; Hyun SJ; Cho HI; Kim TG
J Immunother; 2017 Apr; 40(3):83-93. PubMed ID: 28099196
[TBL] [Abstract][Full Text] [Related]
2. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
4. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
5. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
6. Cross-presentation of HCMV chimeric protein enables generation and measurement of polyclonal T cells.
Nguyen TH; Sullivan LC; Kotsimbos TC; Schwarer AP; Mifsud NA
Immunol Cell Biol; 2010 Aug; 88(6):676-84. PubMed ID: 20195281
[TBL] [Abstract][Full Text] [Related]
7. Cross-presentation of human cytomegalovirus pp65 (UL83) to CD8+ T cells is regulated by virus-induced, soluble-mediator-dependent maturation of dendritic cells.
Arrode G; Boccaccio C; Abastado JP; Davrinche C
J Virol; 2002 Jan; 76(1):142-50. PubMed ID: 11739680
[TBL] [Abstract][Full Text] [Related]
8. Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines.
Meij P; Jedema I; Zandvliet ML; van der Heiden PL; van de Meent M; van Egmond HM; van Liempt E; Hoogstraten C; Kruithof S; Veld S; Marijt EW; von dem Borne PA; Lankester AC; Halkes CJ; Falkenburg JH
J Immunother; 2012 Oct; 35(8):621-8. PubMed ID: 22996368
[TBL] [Abstract][Full Text] [Related]
9. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
10. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
11. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells.
Melenhorst JJ; Solomon SR; Shenoy A; Hensel NF; McCoy JP; Keyvanfar K; Barrett AJ
J Immunother; 2006; 29(4):436-43; discussion 365-6. PubMed ID: 16799339
[TBL] [Abstract][Full Text] [Related]
12. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
13. Delayed IL-21 treatment preferentially expands peptide-specific CD8
Kim SH; Park SY; Lim MC; Lee ES; Lee EG; Han SE; Kim YH; Kwon BS; Choi BK
Immunotherapy; 2019 Apr; 11(6):497-513. PubMed ID: 30760061
[TBL] [Abstract][Full Text] [Related]
14. Activation requirements of circulating antigen-specific human CD8(+) memory T cells probed with insect cell-based artificial antigen-presenting cells.
Guelly C; Küpcü Z; Zalusky D; Karner M; Zehetner M; Schweighoffer T
Eur J Immunol; 2002 Jan; 32(1):182-92. PubMed ID: 11754359
[TBL] [Abstract][Full Text] [Related]
15. A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2- donors.
Foster AE; Bradstock KF; Sili U; Marangolo M; Rooney CM; Gottlieb DJ
Biol Blood Marrow Transplant; 2004 Nov; 10(11):761-71. PubMed ID: 15505607
[TBL] [Abstract][Full Text] [Related]
16. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.
Butler MO; Lee JS; Ansén S; Neuberg D; Hodi FS; Murray AP; Drury L; Berezovskaya A; Mulligan RC; Nadler LM; Hirano N
Clin Cancer Res; 2007 Mar; 13(6):1857-67. PubMed ID: 17363542
[TBL] [Abstract][Full Text] [Related]
17. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.
Tanimoto K; Muranski P; Miner S; Fujiwara H; Kajigaya S; Keyvanfar K; Hensel N; Barrett AJ; Melenhorst JJ
Cytotherapy; 2014 Jan; 16(1):135-46. PubMed ID: 24176543
[TBL] [Abstract][Full Text] [Related]
18. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.
Rohrlich PS; Cardinaud S; Lulè J; Montero-Julian FA; Prodhomme V; Firat H; Davignon JL; Perret E; Monseaux S; Necker A; Michelson S; Lemonnier FA; Charneau P; Davrinche C
Hum Immunol; 2004 May; 65(5):514-22. PubMed ID: 15172452
[TBL] [Abstract][Full Text] [Related]
19. Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.
Engelstein R; Merims S; Eisenberg G; Cohen J; Frank S; Hamburger T; Frankenburg S; Ron I; Isacson R; Grenader T; Steinberg H; Cohen CJ; Peretz T; Lotem M
J Immunother; 2016 Oct; 39(8):321-8. PubMed ID: 27564312
[TBL] [Abstract][Full Text] [Related]
20. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.
Friedman KM; Devillier LE; Feldman SA; Rosenberg SA; Dudley ME
J Immunother; 2011; 34(9):651-61. PubMed ID: 21989413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
